Background Image
Previous Page  164 / 182 Next Page
Information
Show Menu
Previous Page 164 / 182 Next Page
Page Background

163

http://www.DGS-PraxisLeitlinien.de

Nr.

Nachweis

139

Ives TJ, Chelminski PR, Hammett-Stabler CA, Malone RM, Perhac JS, Potisek NM, Shilli-

day BB, DeWalt DA, Pignone MP. Predictors of opioid missues in patients with chronic

pain: a prospective cohort study. BMC Health Services Research 2006; 6: 46.

140

Jacobsen R, Moldrup C, Christrup L. Clinical rationale for administering fentanyl to can-

cer pain patients: two Delphi surveys of pain management experts in Denmark. J Opioid

Manag 2008; 4 (6): 383-391.

141

Kaasa S, Moksnes K, Nolte T, Lefebvre-Kuntz D, Popper L, Kress HG. Pharmacokinetics

of intranasal fentanyl spray in patients with cancer and breakthrough pain. J Opioid

Manage 2010; 6: 17-26.

142

Kalso E, Heiskanen T, Rantio M, Rosenberg PH, Vainio A. Epidural and subcutaneous

morphine in the management of cancer pain: a double-blind cross-over study. Pain

1996; 67: 443-449.

143

Kanpolat Y, Savas A, Ucar T, Torun F. CT-guided percutaneous selective cordotomy for

treatment of intractable pain in patients with malignant pleural mesothelioma. Acta

Neurochirurgica 2002; 144: 595-599.

144

Katz NP, Adams EH, Benneyan JC, Birnbaum HG, Budman SH, Buzzeo RW, Carr DB, Ci-

cero TJ, Gourlay D, Inciardi JA, Joranson DE, Kesslick J, Lande SD. Foundations of opioid

risk management. Clinical Journal of Pain 2007; 23: 103-118.

145

Keating HJ, Kundrat M. Patient-controlled analgesia with nitrous oxide in cancer pain.

Journal of Pain and Symptom Management 1996; 11(2): 126-130.

146

Klepstad P, Kaasa S, Borchgrevink PC. Starting step III opioids for moderate to severe

pain in cancer patients: dose titration: a systematic review. Palliat Med 2011; 25(5):

424-430.

147

Krainick JU, Thoden U. Experience with dorsal column stimulation (DSC) in the opera-

tive treatment of chronic intractable pain. Journal of Neurosurgical Sciences 1974; 18:

187-189.

148

Kress HG, Orońska A, Kaczmarek Z, Kaasa S, Colberg T, Nolte T. Efficacy and tolerability

of intranasal fentanyl spray 50 to 200 microg for breakthrough pain in patients with

cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, cross-

over trial with a 10-month, open-label extension treatment period. Clin Ther 2009;

31(6): 1177-1191.

149

Laverty D. Actiq: an effective oral treatment for cancer related breakthrough pain. Br J

Community Nurs 2007; 12(7): 311.

150

Laverty D. Treating cancer-related breakthrough pain: the oral transmucosal route. Int J

Palliat Nurs 2007; 13(7): 326-331.

151

Laverty DM Davies A. Assessment. In: Davies AN (Hrsg.), Cancer-related breakthrough

pain. Oxford: Oxford University Press; 2006. p. 23-30.

152

Lawrie I, Lloyd-Williams M, Waterhouse E. Breakthrough strong opioid analgesia

prescription in patients using transderaml fentanyl admitted to a hospice. American

Journal of Hospice and Palliative Care 2003; 20: 229-230.

Literaturverzeichnis